Symbols

ETON

Eton Pharmaceuticals·NASDAQ

--(--)

ETON fundamentals

ETON Q4 2025 Earnings

Eton Pharmaceuticals (ETON) released its earnings on Mar 19, 2026: revenue was 19.63M (YoY +68.54%), missed estimates; EPS was 0.15 (YoY +850.00%), beat estimates.

Revenue / YoY

19.63M

+68.54%

EPS / YoY

0.15

+850.00%

Report date

Mar 19, 2026

ETON Earnings Call Summary for Q4,2025

Revenue Surge: Q4 2025 revenue up 83% YoY to $21.3M, driven by new product launches and Alkindi Sprinkle growth.
Profit Margin Expansion: Adjusted EBITDA margin 29% (vs. 18% prior year), with 2026 guidance for >30% margin.
Strategic Acquisitions: $14M HEMANGEOL acquisition to be accretive, targeting $50M+ sales by 2027.
Innovation Pipeline: Desmoda and ET-700 (extended-release Galzin) poised for rapid adoption, with peak sales potential exceeding $100M.
Long-Term Ambition: $200M+ revenue by end-2027, 50% EBITDA margin by 2028, and $500M+ revenue by 2030.

Earnings

EPS

Revenue

Revenue & Expenses

ETON has released its 2025 Q4 earnings report, with revenue of 21.28M, reflecting a YoY change of 82.72%, and net profit of 1.48M, showing a YoY change of 347.99%. The Sankey diagram below clearly presents ETON's revenue sources and cost distribution.

Key Indicators

Eton Pharmaceuticals (ETON) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Eton Pharmaceuticals (ETON)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Eton Pharmaceuticals (ETON)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Eton Pharmaceuticals (ETON)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown